Purpose: Our study was performed to obtain additional information regarding the present diagnostic approaches in breast tumor diagnosis by investigating tumor vessels. We present a new method that helps to capture the morphologic features from power Doppler ultrasound images using a computer-aided system facilitating pixel relation analysis techniques in the region of interest (ROI).

Materials And Methods: 45 solid breast tumors, including 18 benign and 27 malignant histologically proven cases, were studied using quantitative and qualitative parameters with extracted three-dimensional (3D) diagrams. We focused on pixel counting and on physiologic and pathophysiologic vascular analysis over time. P values less than 0.05 using the Wilcoxon, Mann and Whitney's U-test were deemed statistically significant.

Results: One of the two quantitative values, the color range, showed a statistical significance for distinguishing between benign and malignant lesions by counting more pixels in malignant cases. We detected differences in the blood flow dynamics with a characteristic flow texture in 89 % of benign lesions and periodic oscillations which were identified with a diagnostic accuracy of 78 % in malignant cases.

Conclusion: The preliminary results show that the proposed method using power Doppler imaging is feasible and can aid in the classification of breast tumors as benign or malignant.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2008-1027706DOI Listing

Publication Analysis

Top Keywords

breast tumors
12
power doppler
12
benign malignant
12
blood flow
8
malignant
5
[quantitative qualitative
4
qualitative analysis
4
analysis blood
4
breast
4
flow breast
4

Similar Publications

Background: HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy for the management of dyslipidemia by enhancing the clearance of low-density lipoprotein cholesterol receptors, however recent evidence also shows links between PCSK9 and cancer cells.

View Article and Find Full Text PDF

Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis.

JMIRx Med

January 2025

Department of Biochemistry and Medical Genetics, Cancer Center, University of Illinois Chicago, 900 s Ashland, Chicago, IL, 60617, United States, 1 8479124216.

Background: The causes of breast cancer are poorly understood. A potential risk factor is Epstein-Barr virus (EBV), a lifelong infection nearly everyone acquires. EBV-transformed human mammary cells accelerate breast cancer when transplanted into immunosuppressed mice, but the virus can disappear as malignant cells reproduce.

View Article and Find Full Text PDF

The most common carcinoma-related cause of death among women is breast cancer. Early detection is crucial, and the manual screening method may lead to a delayed diagnosis, which would delay treatment and put lives at risk. Mammography imaging is advised for routine screening to diagnose breast cancer at an early stage.

View Article and Find Full Text PDF

Combining 3D cultures such as tumor spheroids and organoids with spatial omics holds great potential for tissue biology and cancer research. Yet, this potential is presently limited by technical and financial challenges of spatial omics methods and 3D cultures. To address this, we combine dye diffusion, the Smart-seq3xpress protocol for deep single-cell gene expression profiling, and dedicated probabilistic inference methods into diffusion Smart-seq3 (Smart-seq3D), to reveal the transcriptome of single cells along with their position along the core-periphery axis of spheroids.

View Article and Find Full Text PDF

Mechanisms related to tumor evasion from NK cell-mediated immune surveillance remain enigmatic. Dickkopf-1 (DKK1) is a Wnt/β-catenin inhibitor, whose levels correlate with breast cancer progression. We find DKK1 to be expressed by tumor cells and cancer-associated fibroblasts (CAFs) in patient samples and orthotopic breast tumors, and in bone.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!